5 Health Services Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 70 points (0.5%) at 14,846 as of Wednesday, Aug. 28, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,865 issues advancing vs. 1,062 declining with 104 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 1.3%, and Fresenius Medical Care AG & Co. KGaA ( FMS), down 0.6%. Top gainers within the industry include Opko Health ( OPK), up 1.6%, Mettler-Toledo International ( MTD), up 1.4% and C.R. Bard ( BCR), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Waters Corporation ( WAT) is one of the companies pushing the Health Services industry lower today. As of noon trading, Waters Corporation is down $0.44 (-0.5%) to $98.01 on light volume. Thus far, 131,814 shares of Waters Corporation exchanged hands as compared to its average daily volume of 461,200 shares. The stock has ranged in price between $97.53-$98.56 after having opened the day at $98.56 as compared to the previous trading day's close of $98.45.

Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. Waters Corporation has a market cap of $8.5 billion and is part of the health care sector. Shares are up 13.0% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Waters Corporation a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Waters Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Waters Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, ResMed ( RMD) is down $0.54 (-1.1%) to $48.25 on light volume. Thus far, 390,439 shares of ResMed exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $47.96-$48.91 after having opened the day at $48.69 as compared to the previous trading day's close of $48.79.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.0 billion and is part of the health care sector. Shares are up 17.4% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate ResMed a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Hologic ( HOLX) is down $0.25 (-1.1%) to $21.77 on light volume. Thus far, 875,506 shares of Hologic exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $21.71-$22.05 after having opened the day at $21.93 as compared to the previous trading day's close of $22.02.

Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for women. Hologic has a market cap of $6.2 billion and is part of the health care sector. Shares are up 14.1% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Hologic as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Hologic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Catamaran ( CTRX) is down $0.45 (-0.8%) to $53.95 on light volume. Thus far, 247,476 shares of Catamaran exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $53.78-$54.49 after having opened the day at $54.22 as compared to the previous trading day's close of $54.40.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $11.4 billion and is part of the health care sector. Shares are up 17.5% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, DaVita HealthCare Partners ( DVA) is down $0.61 (-0.6%) to $108.13 on light volume. Thus far, 294,903 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 874,800 shares. The stock has ranged in price between $107.88-$109.15 after having opened the day at $108.77 as compared to the previous trading day's close of $108.74.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $11.8 billion and is part of the health care sector. Shares are down 1.6% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, increase in net income, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Stocks Turn Lower as 10-Year Yield Hits 3%

Stocks Turn Lower as 10-Year Yield Hits 3%

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Tuesday's Market Movers: CAT, UTX, KO, MMM

Tuesday's Market Movers: CAT, UTX, KO, MMM

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Wall Street Is Totally Forgetting Apple Will Be Giving Away Tons of Cash in 2018

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe

Vivendi Slides After Reports Vincent Bollore Questioned in Corruption Probe